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Abstract
Objective. Long-term evolution of subclinical gut inflammation to overt Crohn’s disease (CD) has been
described in AS patients. The aim of this study was to evaluate macrophage polarization occurring in the
inflamed gut of patients with AS.
Methods. Twenty-seven HLA-B27+ AS patients, 20 CD patients and 17 normal controls were consecu-
tively enrolled. Classic M1 (iNOS+IL-10), resolution phase (iNOS+IL-10+), M2 and CD14+ macrophages
were characterized by immunohistochemistry and flow cytometry. Quantitative gene expression analysis
of IFN-g, IL-4, IL-5, IL-33 and STAT6 was performed by real time PCR.
Results. Classic M1 macrophages were expanded in CD and AS, where resolution phase macrophages
predominate. A large increase in CD163+ (M2) macrophages was observed in AS strictly correlated with
the expression of IL-33, a Th2 cytokine involved in M2 polarization. Unlike in CD, CD14+ macrophages
were virtually absent in the gut of AS patients and controls.
Conclusion. The absence of CD14+ macrophages together with the expansion of resolution phase and
M2 macrophages is the immunological signature of subclinical ileal inflammation in AS.
Key words: ankylosing spondylitis, gut inflammation, M1 macrophages, M2 macrophages, resolution phase
macrophages, interleukin 33.
Introduction
Subclinical gut inflammation occurs in up to 50% of
patients with AS, with long-term evolution to overt
Crohn’s disease (CD) occurring in 710% of AS [13].
Several immunological similarities between gut inflamma-
tion in AS and CD have been described [47], supporting
the concept that this subgroup of AS patients may be
considered a model of early immune alterations related to
CD. Indeed, a lack of hyper-inflammation is observed in the
gut of AS patients, mainly associated with tissue protective
responses. Increased IL-23 expression, without a defined
Th17 polarization [8], expansion of tissue-protective IL-22-
producing NKp44+ natural killer (NK) cells [9] and increased
frequency of IL-10-producing regulatory T (Treg) cells [10]
characterize the immunological signature of subclinical
gut inflammation in AS. Complex regulatory pathways
are involved in the maintenance of intestinal immune
homeostasis, including immune-regulatory cytokines and
cellular elements such as dendritic cells and inhibitory
macrophages, which represent the largest pool of tissue
macrophages in the body [11].
In the last several years macrophages have been
subdivided and categorized on the basis of their activity,
location and cell surface marker expression.
Environmental cues, derived from microbes, damaged
tissues or activated lymphocytes, may induce the emer-
gence of a spectrum of distinct functional macrophage
phenotypes. Borrowing the Th1/Th2 nomenclature,
prevalent M1 (classical/proinflammatory) or M2 (alterna-
tive/anti-inflammatory) macrophage activation have been
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described, which represent extremes of a continuum in a
universe of activation states [12]. Commitment of M1
macrophages may be determined by adaptive immunity
through the stimulation of type 1 inflammatory cytokines
(e.g. IFN-g) and/or by innate immunity with microbial prod-
ucts (such as lipopolysaccharide) stimulating Toll-like
receptors (TLRs) [12]. On the other hand, IL-4, IL-13, IL-
21 and IL-33 are potent inducers of an alternative M2 form
of macrophage activation (reviewed in [13]). M2 macro-
phages seem to exert a prevalent anti-inflammatory role
through the production of IL-10 [14], but are also able to
induce lung eosinophilia and inflammation up-regulating
Ym1, arginase-1 and several chemokines. In fact, M1
and M2 macrophages display distinct chemokine profiles,
with M1 macrophages expressing Th1 cellattracting che-
mokines, such as CXCL9 and CXCL10, and M2 macro-
phages expressing the chemokines CCL17, CCL22 and
CCL24 (reviewed in [13]). Together with M1 and M2
macrophages, another subset, the so-called resolution
phase macrophages, which express markers typical of
M1 macrophages (i.e. COX2 and iNOS) and produce
high levels of M2 cytokines such as IL-10 [15], has
recently been described, highlighting the ability of macro-
phages to change their phenotype during the course of
inflammation.
Unlike blood monocytes or other tissue macrophages,
intestinal macrophages are unresponsiveness to bacterial
stimuli and do not up-regulate co-stimulatory molecules in
response to TLR ligands or cytokines such as IFN-g [16].
This state of unresponsiveness is thought to be depend-
ent upon the reduced expression of TLRs and other func-
tional receptors necessary for macrophage activation (i.e.
CD14) [17]. In chronic inflammatory disorders as well as in
CD this anergic phenotype is lost and CD14-expressing
macrophages accumulate in the inflamed lamina propria
where they are actively involved in the release of pro-in-
flammatory mediators [18], resulting in the induction of
both Th1 and Th17 responses [19, 20]. In the present
study we investigated the frequencies of the different
macrophage subsets in the intestine of AS patients. In
this regard M1, M2, resolution phase and CD14+ macro-
phages were studied and correlated with the expression
of Th1 and Th2 cytokines.
Methods
Patients and controls
Ileal biopsies from patients with AS without symptoms
of bowel inflammation, CD patients with active disease
and normal controls were consecutively obtained.
Demographic and clinical characteristics of patients and
controls are summarized in supplementary Table S1,
available as supplementary data at Rheumatology
Online. The AS group consisted of 27 consecutive HLA-
B27-positive patients fulfilling the modified New York
criteria [21]. Disease activity was evaluated using the
BASDAI [22]. The CD group consisted of 20 patients
and disease activity was evaluated using the CD activity
index [23]. The control group consisted of 17 healthy
subjects undergoing ileocolonscopy for routine evalu-
ation. All patients provided written informed consent and
the study was approved by the ethics committee of the
University of Palermo.
Histomorphological grading
Tissue samples were processed as previously described
[8] and the grade of inflammation was evaluated by an
experienced pathologist (A.R.). Specimens from patients
with AS were divided into three subgroups as previously
described [8]: those with normal gut histology, those with
acute inflammation and those with chronic inflammation.
Acute inflammation was defined by the presence of neu-
trophils and/or eosinophils in the crypt and villus epithe-
lium with preservation of normal architecture. Chronic
inflammation was defined by alterations of the mucosal
architecture, an increased mononuclear cell infiltrate and
formation of basal lymphoid aggregates in the lamina
propria.
Antibodies and reagents
The following primary and secondary antibodies were
used: mouse anti-human CD68 (clone PGM-1, 1:200 dilu-
tion, DAKO, Denmark), mouse anti-human CD14 (clone
TU¨K4, 1:100 dilution, DAKO), mouse anti-human CD163
(clone 10D6, 1:100 dilution, Novocastra, UK), rabbit anti-
human iNOS (1:100 dilution, AbCam, UK), mouse anti-
human IL-10 (1:100 dilution, R&D systems, Abingdon),
rabbit anti-human CXCL9 (1:100 dilution, AbD Serotec,
Oxford), rat anti-human CCL24 (1:100 dilution, Novus
Biological, Littleton, CO, USA), rabbit anti-mouse
Rhodamine Red (1:100 dilution, Invitrogen, Carlsbad,
CA, USA), goat anti-rabbit FITC (1:100 dilution,
Invitrogen), goat anti-rabbit Cy5 (1:100 dilution,
Invitrogen), goat anti-rat Cy5 (1:100, Invitrogen).
Immunohistochemistry
Immunohistochemistry was performed on 5-mm-thick par-
affin-embedded sequential sections as previously
described [8]. The number of CD68-, iNOS-, CD163-
and CD14-expressing cells was determined by counting
the immunoreactive cells on photomicrographs obtained
from three random high-power microscopic fields (original
magnification 400) under a Leica DM2000 optical micro-
scope using a Leica DFC320 digital camera. Results were
reported as the mean (S.D.). To characterize resolution
phase, M1 and M2 macrophages, double and triple stain-
ings were performed on paraffin-embedded sections of
human ileum. Sections were incubated with unlabelled
anti-human-iNOS and IL-10 antibodies (resolution phase
macrophages), iNOS, CD68 and CXCL9 antibodies (M1
macrophages) and CD163, CD68 and CCL24 (M2 macro-
phages) and then treated with FITC- or Rhodamine Red
or Cy-5 conjugated anti-mouse or anti-rabbit antibodies
plus RNasi (200 ng/ml) and counterstained using Toto-3
iodide (642/660; Invitrogen). Confocal analysis was used
to acquire fluorescence staining.
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Flow cytometry analysis of surface and intracellular
antigens
Lamina propria mononuclear cells (LPMCs) were isolated
from ileal biopsies of patients with AS (n= 5) or CD (n= 5)
and from healthy controls (n= 5) as previously described
[10]. The isolated cells were counted and checked for via-
bility using 0.1% Trypan Blue (viability ranged from 90 to
94%). Fresh cell suspension was immediately analysed by
flow cytometry for phenotypical characterization of macro-
phages. The isolated cells were stained with the following
monoclonal antibodies (mAb): anti-human CD68-APC
(BioLegend, San Diego, CA, USA), anti-human CD163-
FITC (BioLegend), anti-human iNOS-PE (BD Biosciences,
San Jose, CA, USA), anti-human CD14-PE (BioLegend),
anti-human IL-10-FITC (BioLegend). Within an extended
lymphocytemonocyte light scatter gate, granulocytes as
well as necrotic cells were excluded. The CD45+CD68+ cell
population was gated and used to discriminate the iNOS+
from the CD163+ and CD14+ macrophages.
Intracellular cytokine staining for IL-10 of iNOS+ cells
was performed as follows: after 2 h of stimulation without
or with lipopolysaccharide (10 ng/ml), brefeldin A
(10 mg/ml) was added to cell cultures. All cultures were
set up in triplicate. After 24 h of culture, cell surface stain-
ing was then conducted with the appropriate antibodies.
After 30 min, cells were thoroughly washed and samples
were analysed by FACSCalibur (Becton Dickinson, USA).
A minimum of 30 000 events were gathered from each
sample. The acquired data were analysed using the
CellQuest software program (Becton Dickinson).
RNA extraction and quantitative TaqMan RT-PCR for
IFN-, IL-4, IL-5, IL-33 and STAT6 in ileal biopsies
The analysis of target gene expression in the intestinal
biopsy samples with quantitative real-time PCR was
performed as previously described [8]. For quantitative
TaqMan real-time PCR, master mix and TaqMan gene
expression assays for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) control and for IFN-g
(Hs00989291_m1), IL-4 (Hs00174122_m1), IL-5
(Hs01548712_g1), IL-33 (Hs01125942_m1) and STAT6
(Hs00598625_m1) were obtained from Applied
Biosystems (Foster City, CA, USA). Samples were run in
triplicate using the Step-One real-time PCR system
(Applied Biosystems).
Statistical analysis
Statistical analysis of quantitative variables was per-
formed using the KruskalWallis non-parametric test,
with Dunn’s post-test. Pearson’s correlation analysis
was utilized to quantify the expression associations
between the genes of interest. P-values <0.05 were
considered significant.
Results
Histomorphological grading
On the basis of gut histology as defined above [8], we
identified two main groups of AS patients: patients
(group 1) displaying normal histology (n= 6) or minor in-
flammatory signs (acute lesions, n= 8) and patients (group
FIG. 1 CD68 expression in the ileum of AS, CD patients and healthy controls.
LPMCs from AS patients (n= 5), CD patients (n= 5) and healthy controls (n= 5) were stained with labelled antibodies as
described in the Methods section. (AE) Dot plot analysis of CD45 + CD68+ cells among isolated LPMCs of one repre-
sentative (A) AS patient, (C) CD patient and (E) healthy control. (BF) Representative microphotographs showing CD68+
macrophages in paraffin-embedded ileal samples from (B) AS and (D) CD patients and (F) healthy controls. Positive cells
are stained brown by specific immunohistochemistry. (BF original magnification 250). (G) Quantification of CD68+ cells
in ileal biopsies from patients and controls. Data are shown as mean (S.D.).
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2) with chronic inflammation (n= 13). As shown in supple-
mentary Table S1, available as supplementary data at
Rheumatology Online, the two groups of AS patients did
not differ significantly by demographic characteristics,
clinical presentation and medications used. A compara-
tive analysis within AS patients was performed by
subgrouping patients with AS with chronic inflammation
vs those with acute inflammation or normal histologic
findings.
Macrophage evaluation
Macrophages were evaluated and enumerated as CD68+
cells in ileal biopsies from AS and CD patients and con-
trols by immunohistochemistry and flow cytometry.
CD68+ cells were found to be significantly increased in
the inflamed lamina propria of AS patients with chronic
gut inflammation and CD patients compared with con-
trols, with the CD samples displaying the greater
number of CD68+ macrophages (Fig. 1). To characterize
macrophage differentiation, M1, M2, resolution phase and
CD14+ macrophages were subsequently evaluated.
iNOS+ macrophages were significantly increased in the
gut of chronic inflamed AS (Fig. 2A, D and G) and CD
(Fig. 2B, E and G) patients when compared with controls
(Fig. 2C, F and G). The M1 phenotype of iNOS-expressing
macrophages was confirmed by confocal microscopy,
demonstrating their co-expression of CXCL9 (an M1-
associated chemokine) in chronic inflamed AS patients
(Fig. 2HK) and CD patients (data not shown).
Macrophages expressing iNOS, classified as M1 macro-
phages, may be induced by adaptive immunity through
IFN-g. Evident overexpression (>10-fold increase) of
IFN-g was detected in patients with CD. On the other
hand, no significant up-regulation of IFN-g was observed
in AS independent of the degree of intestinal inflammation
and controls (Fig. 2L) (P< 0.001).
A subset of iNOS+- and IL-10-expressing macrophages
has been recently demonstrated to characterize the
FIG. 2 iNOS+ macrophages are significantly expanded but differently activated in the ileum of AS and CD patients.
LPMCs from AS patients (n= 5), CD patients (n= 5) and healthy controls (n= 5) were stained with labelled antibodies
as described in the Methods section. (AC) Dot plot analysis of CD68+iNOS+ cells among isolated LPMCs of one
representative (A) AS patient, (C) CD patient and (E) healthy control. (DF) Representative microphotographs showing
iNOS+ cells in paraffin-embedded ileal samples from (D) AS and (E) CD patients and (F) healthy controls. Positive cells are
stained brown by specific immunohistochemistry. (DF original magnification 250). (G) Quantification of iNOS+ cells in
ileal biopsies from patients and controls. (HK) M1 macrophages in the gut of AS patients. (HJ) Single staining iNOS
(green), CD68 (red) and CXCL9 (blue), respectively. (K) Merged triple staining. (L) Relative mRNA quantification of IFN-g
was assessed by RT-PCR in the ileal biopsy specimens from patients and controls. Data are shown as mean (S.D.).
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resolution phase of tissue inflammation [15]. Resolution
phase macrophages were evaluated by FACS
(CD68+iNOS+IL-10+ cells) and laser confocal microscopy
(iNOS+IL-10+ cells) in the ileum of patients and controls.
iNOS+IL-10+ resolution phase macrophages were signifi-
cantly increased only in AS patients with chronic gut
inflammation (Fig. 3EH) when compared with CD patients
(Fig. 3IL) or controls (Fig. 3AD).
CD163+ macrophages are significantly expanded
and correlated with expression of IL-33 in
the intestinal mucosa of AS patients
M2 (CD163+ cells) macrophages were found to be
increased in the inflamed ileal specimens from AS patients
displaying chronic gut inflammation (Fig. 4A, D and G)
when compared with CD patients (Fig. 4B, E and G) and
controls (Fig. 4C, F and G). The M2 phenotype of CD163-
expressing macrophages was confirmed by confocal
microscopy demonstrating their co-expression of CCL24
(an M2-associated chemokine) in chronic inflamed AS
patients (Fig. 4HM) and CD patients (data not shown).
The mRNA levels of IL-4, IL-5, IL-33 and STAT6, which
are involved in M2 polarization, were also evaluated. IL-4,
IL-5 and STAT6 were similarly up-regulated in the
inflamed gut of both CD and AS patients with chronic
gut inflammation (Fig. 5AC). On the other hand IL-33, a
potent inducer of M2 polarization [24], was significantly
up-regulated only in the gut of chronic inflamed AS
patients (>20-fold increase) (Fig. 5D) and directly corre-
lated with the numbers of CD163+ cells (r= 0.82,
P= 0.0046) (Fig. 5E), suggesting a role for IL-33 in the
commitment of M2 macrophages in the gut of AS.
CD14+ macrophages are virtually absent in the
subclinical gut inflammation of AS patients
Macrophages interact with bacteria and their products
through CD14, a surface receptor involved in the detec-
tion of lipopolysaccharide and other associated molecular
patterns [11]. Thus we examined whether the subclinical
gut inflammation of AS was characterized by the
FIG. 3 Increased frequency of iNOS+IL-10+ macrophages in isolated LPMCs from patients with AS and CD.
LPMCs from AS patients (n= 5), CD patients (n= 5) and healthy controls (n= 5) were stained with labelled antibodies
as described in the Methods section. (AI) Dot plot analysis of CD68+iNOS+IL-10+ cells in isolated LPMCs from one
representative (A) health control, (E) AS patient and (I) CD patient. (BD) Resolution phase macrophages in healthy
controls. (B, C) Single staining for IL-10 and iNOS, respectively. (D) Merged double staining for IL-10 (green) and iNOS
(red). (FH) resolution phase macrophages in AS patients. (F, G) Single staining for IL-10 and iNOS, respectively.
(H) Merged double staining for IL-10 (green) and iNOS (red). (JL) Resolution phase macrophages in CD patients.
(J, K) Single staining for IL-10 and iNOS, respectively. (L) Merged double staining for IL-10 (green) and iNOS (red).
(M, N) Isotype control antibodies on representative sections from AS patients.
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expression of CD14. As shown in Fig. 6, CD14+ macro-
phages were rarely detected in the gut of normal controls
(Fig. 6A, D and G) and AS patients independent of the
degree of intestinal inflammation (Fig. 6B, E and G).
Conversely, greater numbers of CD14+ macrophages
were observed in CD patients (Fig. 6CG), suggesting
that the presence of this subset of macrophages immuno-
logically differentiates the gut of AS from that of CD
patients.
Discussion
Quantitative and qualitative alterations in the pattern of
secreted mediators produced by intestinal macrophages
might represent a major factor contributing to the patho-
genesis of gut involvement in both AS and CD.
Macrophages are not a homogeneous population and
different pathways of macrophage activation have been
described in humans according to their phenotype and
function [12]. Similar to the Th1/Th2 paradigm, macro-
phages have been classified in two main populations:
classically activated macrophages (M1), which are the
main source of soluble proinflammatory cytokines and
are associated with a proinflammatory state, and alterna-
tively activated macrophages (M2), which are associated
with an anti-inflammatory state and/or Th2-mediated
tissue inflammation [12]. Another subset of macrophages,
the so-called resolution phase macrophages have been
recently described [15]. These cells are neither classically
nor alternatively activated, but possess aspects of
both definitions consistent with an immune regulatory
phenotype.
In non-inflamed mucosa, resident macrophages lack
the expression of innate immune co-receptor CD14 and
do not produce proinflammatory cytokines against com-
mensal bacteria [17]. In the inflamed mucosa, as observed
FIG. 4 CD163+ macrophages are significantly expanded in the ileum of AS and CD patients.
LPMCs from AS patients (n= 5), CD patients (n= 5) and healthy controls (n= 5) were stained with labelled antibodies
as described in the Methods section. (AC) Dot plot analysis of CD68+CD163+ cells in isolated LPMCs from one
representative (A) AS patient, (B) CD patient and (C) healthy control. (DF) Representative microphotographs showing
CD163+ cells in paraffin-embedded ileal samples from (D) AS and (E) CD patients and (F) healthy controls. Positive cells
are stained brown by specific immunohistochemistry. (DF original magnification 250). (G) Quantification of CD163+
cells in ileal biopsies from patients and controls. Data are shown as mean (S.D.). (HK) M2 macrophages in AS patients.
(HJ) Single staining for CD163 (red), CD68 (green) and CCL24 (blue), respectively. (K) Merged triple staining for CD163,
CD68 and CCL24.
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in CD, expansion of CD14+ intestinal macrophages occurs
and contributes to the pathogenesis of disease via the
production of IL-23 and TNF-a and induction of Th1 and
Th17 responses [1820].
Impairment of M1-derived mediators and expansion of
M2 macrophages has been demonstrated in the colon
and synovial fluid of AS patients [7, 25]. How the different
subsets of macrophages are represented in the inflamed
ileum of AS patients is still unclear. In the present study
we studied the frequency of M1, M2, resolution phase
and CD14+ macrophages in the gut of AS patients
with subclinical gut inflammation and investigated the
transcript levels of cytokines and transcription factors.
Classically activated M1 macrophages (iNOS+IL-
10CXCL-9+) were significantly expanded in the inflamed
gut of both chronic inflamed AS and CD patients.
Although a plethora of stimuli may induce M1 polarization,
M1 macrophages may be induced in response to
type 1 inflammatory cytokines (e.g. IFN-g) and/or micro-
bial products (e.g. lipopolysaccharide) through TLR stimu-
lation [25, 26].
Analysis of M1 polarization in our study showed that
adaptive immunity, mainly through the Th1 cytokine
IFN-g, seems to be the main inducer of M1 macrophage
polarization in CD. The absence of a Th1 signature
observed in the subclinical gut inflammation of AS
patients in this and other reports may suggest a role of
intestinal microbiota in driving the classic M1 macrophage
response we demonstrated in this study..
Despite the increased presence of M1 polarized macro-
phages, in AS patients we observed a lack of excessive
intestinal inflammation as demonstrated by the absence
of intestinal signs and symptoms. The significant increase
in iNOS+IL-10+ cells (defined as resolution phase macro-
phages) together with the large increase in the numbers of
CD163+ ileal macrophages (M2 or alternatively activated)
observed in our study in AS patients with chronic gut
inflammation could counterbalance the activation of M1
macrophages, inhibiting the transition through a chronic
inflammatory intestinal disease. M2 macrophages in
particular are known to exert an anti-inflammatory role
and to promote tissue repair and remodelling [14]. M2
polarization is mainly induced by Th2 cytokines such as
IL-4 (through the activation of STAT6), IL-13 and IL-33 [14,
24]. M2-activated macrophages produce IL-10 and favour
Th2-polarized T cell responses [14]. A cytokine milieu
characterized by high levels of Th2-related cytokines
and transcription factors such as IL-4, IL-13 and STAT6
was found in both AS and CD. On the other hand, signifi-
cantly increased IL-33 expression was observed in AS
patients, whereas no change was observed in CD. IL-33
is a cytokine of the innate immune system that is released
FIG. 5 IL-4, IL-5, STAT6 and IL-33 expression in the ileum of AS and CD patients and healthy controls.
Relative mRNA quantification of (A) IL-4, (B) IL-5, (C) STAT6 and (D) IL-33 was assessed by RT-PCR in all the ileal biopsy
specimens from patients and controls. IL-33 mRNA expression was differentially expressed in the gut of (D) AS patients
and was correlated with the numbers of (E) CD163+ macrophages. Data are shown as mean (S.D.); P< 0.05.
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in response to bacterial and/or viral stimuli and is up-
regulated in human inflammatory diseases [2730]. The
strong expression of IL-33 and its relationship with
the numbers of CD163+ macrophages observed could
suggest a key role of this cytokine in regulating macro-
phage polarization in the AS gut. In this regard, serum
levels of IL-33 have been demonstrated to be elevated
in AS patients and to enhance TNF-a production by per-
ipheral blood mononuclear cells and inducing neutrophil
migration [31].
In non-inflamed lamina propria, to maintain mucosal
homeostasis, macrophages lack the expression of
CD14, the innate immune co-receptor of TLR7 and TLR9
[32] and display prominently an anergic phenotype [17]. In
the present study we confirm previous results that show
that CD14+ macrophages are expanded in CD [18] and
demonstrate that CD14+ macrophages are not present
in the lamina propria of AS patients with subclinical
gut inflammation. CD14+ macrophages have been impli-
cated in disease pathogenesis via production of IL-23 and
TNF-a[19, 20] and induction of Th1 and Th17 responses.
Together with the absence of a clear Th1/Th17 response
[14, 15], this behaviour appears to clearly differentiate
the immunological signature of patients with AS from
those with CD. The down-regulation of CD14 expression
in AS could be explained by the high levels of intestinal
TGF-b and IL-10 [10, 33], which are known to be
involved in the down-regulation of the membrane-
associated CD14 [34].
In conclusion, a balanced macrophage activation
seems to be present in the gut of AS patients with chronic
inflammation where CD14+ macrophages are absent and
classic M1 macrophages are increased, presumably in
response to the microbial flora. The M1 macrophage
expansion may be counterbalanced by the increased
numbers of resolution phase and M2 macrophages. The
differences in the immunological behaviour observed in
the gut of AS patients with normal histology and/or
acute inflammation compared with those with chronic
inflammation might represent a different evolutionary
FIG. 6 CD14+ macrophages are significantly expanded only in the ileum of CD patients.
LPMCs from AS patients (n= 5), CD patients (n= 5) and healthy controls (n= 5) were stained with labelled antibodies as
described in the Methods section. (AC) Dot plot analysis of CD68+CD14+ cells in isolated LPMCs from one represen-
tative (A) AS patient, (B) CD patient and (C) healthy control. (DF) Representative microphotographs showing CD14+ cells
in paraffin-embedded ileal samples from (D) AS and (E) CD patients and (F) healthy controls. Positive cells are stained
brown by specific immunohistochemistry. (DF original magnification 250). (G) Quantification of CD14+ cells in ileal
biopsies from patients and controls. Data are shown as mean (S.D.); *P< 0.05.
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step in a continuum of inflammatory processes. It is
not possible, however, to exclude that acute inflamed
and chronic inflamed intestine of AS patients may be
a distinct pathologic disease. The absence of functional
studies and the difficulty in isolating intestinal macro-
phages to demonstrate specific transcriptional profile
differences prevents us from reaching any definitive
conclusions. Further studies are also required to specific-
ally address the micro-environmental cues conditioning
the immunological changes that characterize the evolution
of AS subclinical gut inflammation towards a clinically
evident CD.
Rheumatology key messages
. Expansion of M2 and resolution phase macro-
phages predominates in the ileum of AS patients.
. IL-33 is overexpressed in the inflamed ileum of AS
patients.
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